POINT-Logo-Colour (blue).png
POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress
October 17, 2022 08:30 ET | POINT Biopharma
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA...
POINT-Logo-Colour (blue).png
POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET | POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
August 08, 2022 08:30 ET | POINT Biopharma
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at...
POINT-Logo-Colour (1).png
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
May 05, 2022 09:15 ET | POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT-Logo-Colour (1).png
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
April 26, 2022 08:30 ET | POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
POINT-Logo-Colour (1).png
POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting
April 11, 2022 16:30 ET | POINT Biopharma
POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...
Nextnav logo.png
NextNav Showcases APNT Backup to GNSS at European Commission's Joint Research Centre’s Trial
February 01, 2022 13:36 ET | NextNav
SUNNYVALE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NextNav (Nasdaq: NN) today announced that it has recently participated in the European Commission’s Joint Research Centre (JRC) alternative...
NextNav and Satelles Collaborate to Establish an Alternative PNT Testbed in the San Francisco Bay Area
October 05, 2021 09:00 ET | NextNav; Satelles, Inc.
SUNNYVALE, Calif. and RESTON, Va., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NextNav and Satelles, Inc. today announced that they have partnered on an alternative positioning, navigation, and timing (PNT)...
POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor
September 28, 2021 08:00 ET | POINT Biopharma
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic...
POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC
September 23, 2021 08:00 ET | POINT Biopharma
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS,...